-Pfizer looks good to Goldman Sachs. Says it’s a buy! [Yahoo!Finance]

-Alcon’s cortisol derivate, anecortave acetate, works in Hopkins glaucoma study. [MedPage Today]

-Sanofi rules out BMS buyout. [Bloomberg]

-GSK’s Tyverb (lapatinib) for advanced breast cancer will not get NHS funding from UK. [FierceBiotech]

Financings for Today

-GlycoVaxyn has raised $22M (EUR 17M) from Edmond de Rothschild Investment Partners, Index Ventures and Sofinnova Partners. GlycoVaxyn is developing conjugated vaccines that make production of glycoproteins easier and more affordable. [FierceVaccines]

-Optimer Pharmaceuticals has raised $32.9M worth of new shares and warrants. The cash will go to general admin expenses and to further advance Optimer’s lead drug, fidaxomicin (OPT-80), for C. diff and traveler’s diarrhea, currently in a Phase 3 trial. [Xconomy]

And that’s that…

Image from IguanaBio

Related Posts